Breast Cancer Experts Look Ahead to Exciting Programs in 2023

Roshni Rao, MD, FACS, discussed the use of neoadjuvant chemoimmunotherapy and its complications in the treatment of patients with triple-negative breast cancer.

In this Q&A we discuss the role of PARP inhibitors in cancer treatment, their role in triple-negative breast cancer patients and look forward to ongoing trials in this setting.

The phase 3 IMpassion030 trial did not find a survival benefit when atezolizumab was added to chemotherapy after surgery for patients with triple-negative breast cancer.

In this interview we discuss long-term data on the anti–PD-L1 immunotherapy atezolizumab in metastatic triple-negative breast cancer.

Lower risk of disease progression following treatment with atezolizumab and carboplatin for metastatic triple-negative breast cancer appears to be associated with increases in tumor infiltrating lymphocytes and tumor mutational burden.

Data from the phase 2 KEYLYNK-009 study indicate a lower rate of treatment-related adverse effects with pembrolizumab plus olaparib compared with pembrolizumab plus chemotherapy in those with triple-negative breast cancer.